Subscribe to our RSS feeds RSS | Login | Register  
 

MM&M's New Drug Dossier combines promotional insights with clinical information to offer marketers the first complete online resource for newly approved drugs. Each dossier features agency rosters, marketing strategy, recent news coverage, clinical insights from Monthly Prescribing Reference (MPR), market data from IMS Health, physician outlook from the GfK US Healthcare Companies and late-stage pipeline candidates from Adis R&D Insight.

For more information or to subscribe click here »



SAMPLE DOSSIER: Vyvanse

SAMPLE DOSSIER: Vyvanse

November 21, 2007

Shire's marketing strategy with Vyvanse involves converting patients from category leader Adderall XR over to the new drug, which launched in June after its February approval to treat symptoms of ADHD in children aged 6 to 12.
 

FULL DRUG INDEX

Adcirca

Afluria

Akten

Altabax

Alvesco

Angeliq

Arcalyst

Azasite

Azor

Banzel

Brovana

Bystolic

Calomist

Cimzia

Cleviprex

Combigan

Divigel

Doribax

Elestrin

Endometrin

Entereg

Epiduo Gel

Evamist

Exforge 5/160

Fexmid

Flector Patch

Fosteum

Fusilev

Ibudone

Implanon

Intelence

Invega

Isentress

Ixempra

Ixiaro

Janumet

Kapidex

Kinrix

Kuvan

Lexiscan

Lialda

Liquadd

Lusedra

Lybrel

Moxatag

Neupro

Nplate

Omnaris

Ozurdex

Pataday

Patanase

PegIntron/REBETOL

Pentacel

Perforomist

PrandiMet

Pristiq

Promacta

Pylera

Reclast

Recothrom

Relistor

Renvela

RiaSTAP

Rotarix

Samsca

Savella

Selzentry

Simcor

Simponi

Symbicort 160/4.5

Symbyax

Tasigna

Tekturna

Tekturna HCT

Torisel

Totect

Toviaz

Treanda

Treximet

Triesence

TriLipix

Tykerb

Tyzeka

Uloric

Vectical Ointment

Veramyst

Veregen

Vimpat

Voltaren Gel

Xenazine

Xyntha

Xyzal

Ziana

Most Recent Approvals

Ozurdex

Ozurdex

June 29, 2009

For the treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).
 
Adcirca

Adcirca

June 12, 2009

United Therapeutics will promote to healthcare professionals who treat pulmonary arterial hypertension (PAH). It will be positioned as a first line oral agency for the treatment of PAH.
 
Samsca

Samsca

June 01, 2009

Samsca is an oral selective vasopressin antagonist for the treatment of patients with clinically significant hypervolemic and euvolemic hyponatremia including patients with heart failure, cirrhosis and the syndrome of inappropriate anti-diuretic hormone (SIADH).
 
Simponi

Simponi

May 11, 2009

The efficacy and safety of Simponi have been evaluated in one of the most comprehensive clinical development programs for an anti-TNF-alpha therapy, which included simultaneous studies in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
 
Savella

Savella

April 23, 2009

Savella will be marketed directly to physicians via sales reps and professional journals. It will be positioned as a first line treatment for fibromyalgia.
 
Kapidex

Kapidex

April 23, 2009

Takeda has a lot of experience marketing PPIs with lansoprazole (Prevacid).
 
Symbyax

Symbyax

April 17, 2009

Symbyax is now the first drug approved by the FDA for the acute treatment of treatment-resistant depression (TRD).
 
Ixiaro

Ixiaro

April 17, 2009

IXIARO will be positioned as the "safe and effective prevention of Japanese Encephalitis, protecting travelers from an unpredictable and potentially devastating illness".
 
Epiduo Gel

Epiduo Gel

March 20, 2009

Epiduo Gel 0.1% / 2.5% is the first and only topical acne medication that combines a retinoid and benzoyl peroxide—and targets three out of the four causes of acne in a single product.
 
Uloric

Uloric

March 18, 2009

Experts recognize that managing serum uric acid (SUA) to a target level of less than 6.0 mg/dL is the key to managing hyperuricemia in patients with gout.
 
Popular Topics
Advertising Agency Biotech Brand Consumer CRM Digital Direct Marketing Direct To Consumer (DTC) Direct To Patient (DTP) Education & Awareness Event Government Launch Magazine Marketing & Communications Media Medical Journal Online Pharmaceutical Product Professional Promotion Public Relations (PR) Sales Force